{"nctId":"NCT01276756","briefTitle":"Efficacy of Nitazoxanide in the Treatment of Chronic Hepatitis C Virus (HCV)","startDateStruct":{"date":"2010-12"},"conditions":["Chronic Hepatitis c"],"count":100,"armGroups":[{"label":"Standard of care","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Pegylated interferon alfa-2a","Drug: Ribavirin"]},{"label":"Triple therapy","type":"EXPERIMENTAL","interventionNames":["Drug: Pegylated interferon alfa-2a","Drug: Nitazoxanide","Drug: Ribavirin"]}],"interventions":[{"name":"Pegylated interferon alfa-2a","otherNames":["Reiferon retard"]},{"name":"Nitazoxanide","otherNames":["Xerovirin-C"]},{"name":"Ribavirin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Adult (male or female), 18 to 65 years of age, with chronic HCV infection\n* BMI \\< 35\n* Liver biopsy showing chronic hepatitis with significant fibrosis using Ishak scoring system\n* Compensated liver disease; serum bilirubin \\< 1.5 mg/dl, INR (international normalized ratio) no more than 1.5, serum albumin \\> 3.4, platelet count \\> 75,000 mm, and no evidence of hepatic decompensation (hepatic encephalopathy or ascites)\n* Acceptable hematological and biochemical indices (hemoglobin 13g/dl for men and 12 g/dl for women; neutrophil count 1500/mm3 or more and serum creatinine \\< 1.5 mg/dl\n* Patients must be serum hepatitis B surface antigen (HBsAg) negative\n* Negative Antinuclear Antibodies (ANA) or titer of \\< 1:160\n* Serum positive for anti-HCV antibodies and HCV-RNA\n* Abdominal Ultrasound obtained within 3 months prior to entry in the study\n* Electrocardiogram for men aged \\> 40 years and for women aged \\> 50 years\n* Normal fundus examination\n* Ensure strict measures to avoid conception for both male and female participants by using a proper contraception measure all throughout the course of treatment and six months later\n* Female patients must not breast feed during therapy\n\nExclusion Criteria:\n\n* Patients who previously received interferon\n* HgbA1c \\> 7.5 (glycoslylated haemoglobin)or history of diabetes mellitus\n* BMI \\> 34\n* Women who are pregnant or breast-feeding\n* Males whose female partners are either pregnant or of child-bearing potential or not using birth control and are sexually active\n* Other causes of liver disease including autoimmune hepatitis\n* Transplant recipients receiving immune suppression therapy\n* Screening tests positive for anti-HAV IgM Ab, HBsAg, anti-HBc IgM Ab or anti-HIV Ab\n* Decompensated cirrhosis, history of variceal bleeding, ascites, hepatic encephalopathy, CTP score \\> 6 (Child-Turcot-Pugh) or MELD score \\> 8\n* Absolute neutrophil count \\< 1500 cells/mm3; platelet count \\< 135,000 cells/mm3; hemoglobin \\< 12 g/dL for women and \\< 13 g/dL for men; or serum creatinine concentration â‰¥ 1.5 times ULN (upper limit of normal)\n* Hypothyroidism or hyperthyroidism not effectively treated with medication\n* Alcohol consumption of \\> 40 grams per day or an alcohol use pattern that will interfere with the study\n* History or other clinical evidence of significant or unstable cardiac disease\n* History or other clinical evidence of chronic pulmonary disease associated with functional impairment\n* Serious or severe bacterial infection(s)\n* History of severe or uncontrolled psychiatric disease, including severe depression, history of suicidal ideation, suicidal attempts or psychosis requiring medication and/or hospitalization\n* History of uncontrolled severe seizure disorder\n* History of immunologically mediated disease requiring more than intermittent anti-inflammatory medications for management or that requires frequent or prolonged use of corticosteroids\n* Patients with clinically significant retinal abnormalities\n* History of hypersensitivity or intolerance to nitazoxanide or any of the excipients comprising the nitazoxanide tablets, peginterferon alfa-2a injectable solution or ribavirin tablets","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Sustained Virologic Response","description":"sustained virological response is defined as a negative HCV PCR at 180 days after the end of treatment (End of treatment being at 48 weeks for Group A, 52 weeks for Group B). For any patient who stopped treatment prematurely (e.g. due to adverse events) SVR was defined as a negative HCV PCR (polymerase chain reaction) at 180 days after the last dose of all medications (interferon, ribavirin and nitazoxanide)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":"0.5"},{"groupId":"OG001","value":"25","spread":"0.5"}]}]}]},{"type":"SECONDARY","title":"Rapid Virological Response","description":"A rapid virologic response is defined as a negative HCV PCR 4 weeks after treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]}]},{"type":"SECONDARY","title":"Early Virological Response","description":"A complete early virologic response is defined as a negative HCV PCR 90 days after the start of pegylated interferon.\n\nA partial early virologic response is defined as a decrease of 2 or more log in HCV PCR at 90 days after the start of pegylated interferon","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]}]},{"type":"SECONDARY","title":"End-of-treatment Response","description":"An end-of-treatment response is defined as a negative HCV PCR at 48 weeks after the start of pegylated interferon and ribavirin","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"29","spread":null}]}]}]},{"type":"SECONDARY","title":"Safety of Nitazoxanide (Number of Participants Experiencing Adverse Events)","description":"The occurence of adverse events that could be linked temporally and reasonably to the administration of the tested drug.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"47","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":50},"commonTop":["Fever","Fatigue","musculoskeletal pains","headache","itching"]}}}